2‑Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety

• Published in: Journal of medicinal chemistry Vol. 61; no. 7; pp. 3114 - 3125
• Main Authors: Dow, Robert L, Ammirati, Mark, Bagley, Scott W, Bhattacharya, Samit K, Buckbinder, Leonard, Cortes, Christian, El-Kattan, Ayman F, Ford, Kristen, Freeman, Gary B, Guimarães, Cristiano R. W, Liu, Shenping, Niosi, Mark, Skoura, Athanasia, Tess, David
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 12-04-2018
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.8b00152

Studies have linked the serine-threonine kinase MAP4K4 to the regulation of a number of biological processes and/or diseases, including diabetes, cancer, inflammation, and angiogenesis. With a majority of the members of our lead series (e.g., 1) suffering from time-dependent inhibition (TDI) of CYP3A4, we sought design avenues that would eliminate this risk. One such approach arose from the observation that carboxylic acid-based intermediates employed in our discovery efforts retained high MAP4K4 inhibitory potency and were devoid of the TDI risk. The medicinal chemistry effort that led to the discovery of this central nervous system-impaired inhibitor together with its preclinical safety profile is described.